Comprehensive analysis of differentially expressed profiles of IncRNAs and mRNAs reveals ceRNA networks in the transformation of diffuse large B-cell lymphoma

LU TIAN, YANGYAN HE, HONGKUN ZHANG, ZIHENG WU, DONGLIN LI and CHENGFEI ZHENG

Department of Vascular Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China

Received December 24, 2016; Accepted November 16, 2017

DOI: 10.3892/ol.2018.8722

Abstract. Diffuse large B-cell lymphoma (DLBCL) is one of the malignancies with a high mortality rate. The molecular mechanisms involved in transformation of DLBCL remain unclear. Therefore, it is critically important to investigate the biological mechanisms of DLBCL. Accumulating evidence indicates that long non-coding RNAs (IncRNAs) serve key functions in tumorigenesis, cancer progression and metastasis. Compared with follicular lymphoma (FL), a total of 123 upregulated IncRNAs and 192 downregulated IncRNAs in DLBCL were identified. Subsequently, a specific DLBCL-associated competing endogenous RNA (ceRNA) network and a specific FL-associated ceRNA network was constructed. Gene Oncology and Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that differentially expressed lncRNAs served key functions in regulating signal transduction, transcription, cell adhesion, development and protein amino acid phosphorylation. Furthermore, the molecular functions of PRKCG antisense RNA 1, HLA complex P5, OIP5 antisense RNA 1, growth arrest specific 5 and taurine upregulated 1 were investigated, and it was revealed that these lncRNAs served important functions in regulating a series of biological processes, including anti-apoptosis, cell cycle, DNA repair, response to oxidative stress and transcription. The present study may provide a potential novel therapeutic and prognostic target for the treatment of DLBCL.

Introduction

Follicular lymphoma (FL) accounts for ~30% of all non-Hodgkin's lymphomas (1). FL is usually indolent, and patients have long survival rates (2). However, in 25-60% of all patients with FL, FL undergoes transformation into diffuse large B-cell lymphoma (DLBCL), which results in rapid progression, treatment resistance and mortality (2). DLBCL is a malignancy with a high mortality rate due to the lack of biomarkers for early diagnosis and efficient therapeutic strategies (3). Therefore, it is critically important to identify biomarkers for DLBCL and to investigate the biological mechanisms of DLBCL.

Accumulating evidence reveals that IncRNAs serve key functions in tumorigenesis, cancer progression and metastasis (4,5). Long non-coding RNAs (IncRNAs), a major class of non-coding RNAs, are RNA polymerase II transcripts that are >200 bp and do not encode proteins (6). Multiple reports have revealed that IncRNAs may regulate the expression of protein-coding genes through transcriptional, post-transcriptional, post-translational and/or epigenetic regulation (7,8). Previously, a number of studies had revealed that lncRNA expression may be deregulated in various types of human cancer (9,10). For example, prostate cancer associated 3 (non-protein coding) was significantly upregulated in prostate cancer, compared with health tissues (11). Additionally, it was indicated that H19, imprinted maternaly expressed transcript (non-protein coding) was overexpressed in hepatocellular carcinoma and that this overexpression was disease-associated (12). According to the competing endogenous RNA (ceRNA) hypothesis (13), ceRNAs may compete for the same micro RNA (miRNA) response elements to regulate each other (14). Previously, studies revealed that the ceRNA network may serve prognostic or diagnostic functions in cancer. For example, Zhou et al (15,16) identified dysregulated IncRNA-associated ceRNA networks as biomarkers for pancreatic and ovarian cancer. Previously, a number of studies indicated that altered expression of certain IncRNAs may be an important mechanism of DLBCL progression. A number of IncRNAs, including HOX transcript antisense RNA (HOTAIR) (17), tumor protein p53 pathway corepressor 1 (lincRNA-p21) (18), paternally...
expressed 10 (PEG10) (19), MEF2C antisense RNA 2, SACS antisense RNA 1, RP11-25K19.1, MME antisense RNA 1, RP11-360F5.1 and CSMD2 antisense RNA 1 (20) which were significantly associated with the survival outcomes of DLBCL. Peng et al. (21,22) reported that hepatocellular carcinoma upregulated long non-coding RNA and leukemia-associated non-coding IGf1r activator RNA 1 were associated with cell proliferation in DLBCL. Zhou et al. (23) identified a 17-inLncRNA signature for subtype classification and prognosis prediction by analyzing differentially expressed lncRNAs between germinal center B-cell-like and activated B-cell-like subtypes. However, the molecular mechanisms and functions underlying the involvement of lncRNAs in the transformation of DLBCL remain largely unknown.

In the present study, the aim was to identify differentially expressed lncRNAs and mRNAs involved in the transformation of DLBCL by analyzing a cohort of previously published datasets from the Gene Expression Omnibus (GEO). In an attempt to provide novel information on the molecular mechanisms and functions of lncRNAs, a bioinformatics analysis was conducted to identify the lncRNA-miRNA-mRNA regulatory axis in DLBCL. Subsequently, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis was performed in order to investigate the potential functions of dysregulated lncRNAs.

Materials and methods

Microarray data and data preprocessing. Microarray data was downloaded from a previous study by Brodtkorb et al. (24), which was referenced in the GEO database (accession no. GSE53820; www.ncbi.nlm.nih.gov/geo/). In this dataset, preprocessed using the limma package in R (version, 3.34.2; www.r-project.org/), expression profiles were obtained from a total of 81 biopsies, which were taken from 41 patients diagnosed with FL using the Affymetrix HG U133 Plus 2.0 Gene Chip (Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Of these, 49 biopsies (43 with a histological diagnosis of FL and 6 with DLBCL) were sourced from 24 patients with a subsequent transformation to a higher-grade lymphoma (namely, DLBCL) and 32 biopsies were sourced from 17 patients without any sign of transformation. The cut-off values used for selecting differentially expressed mRNAs were fold change ≥2 and P<0.05.

lncRNA classification pipeline. In order to evaluate the expression of lncRNAs in microarray data, a pipeline, previously described by Zhang et al. (25), was employed to identify the probe sets uniquely mapped to lncRNAs from the Affymetrix array by using the following criteria: i) For the probe sets with Refseq IDs, those labeled as ‘NR’ (where NR indicates non-coding RNA in the Refseq database) were retained; ii) for the probe sets with Ensembl gene IDs, those annotated with ‘lncRNA’, ‘processed transcripts’, ‘non-coding’ or ‘misc_RNA’ in Ensembl annotations were retained; iii) the probe sets obtained were refined by filtering pseudogenes, ribosomal RNAs, microRNAs, transfer RNA (tRNAs), small nuclear RNAs and small nucleolar RNAs. A total of 2,448 annotated lncRNA transcripts with corresponding Affymetrix probe IDs were obtained. The cut-off values used for selecting differentially expressed lncRNAs were fold change ≥2 and P<0.05.

Functional group analysis. GO analysis and KEGG analysis were employed to determine the biological functions of the identified differentially expressed mRNAs, based on the freely available online MAS 3.0 system from CapitalBio Corporation (http://bioinfo.capitalbio.com/mas3/; Beijing China). The P-value (hypergeometric P-value) denotes the significance of the pathway associated with the conditions. P<0.05 was considered to indicate a statistically significant difference.

Construction of the lncRNA-miRNA-mRNA network. To predict the functions of the differentially expressed lncRNAs, co-expression networks of differentially expressed lncRNAs were constructed for further bioinformatics analysis, as previously described by Guttman and Rinn (26) and Shen et al. (27). The StarBase dataset (27) was used to identify potential dysregulated lncRNA-miRNA pairs. StarBase and TargetScan (28) databases were also used to identify miRNA-mRNA pairs. Finally, a co-expression network based on association analysis between the differentially expressed lncRNAs and mRNAs was constructed. The lncRNA-mRNA interaction was integrated into the co-expression networks according to positive regulation and only gene pairs with |RI|>0.5 were selected.

Hierarchical clustering analysis. To generate an overview of lncRNA and mRNA expression profiles between FL and DLBCL, hierarchical clustering analysis was performed based on the expression values. Cytoscape 3.0 was applied to plot the lncRNA-miRNA-mRNA ceRNA networks involved in the transformation of DLBCL.

Statistical analysis. All numerical data (log-transformed) are presented as the mean ± standard deviation of at least 3 determinations. Statistical comparisons between groups of normalized data were performed using a Student's t-test (unpaired) or Mann-Whitney U-test according to the test conditions. P<0.05 was considered to indicate a statistically significant difference with a 95% confidence level. All of the above statistical analyses are analyzed with R software, version 3.2.4 (https://www.r-project.org/).

Results

Systematic comparison of differentially expressed mRNAs and lncRNAs between FL and DLBCL. In order to compare differentially expressed mRNAs and lncRNAs between FL and DLBCL, a publicly available gene expression database (accession no. GSE53820) was utilized. This database includes 75 FL samples and 6 DLBCL samples. Differentially expressed mRNAs in the GSE53820 database were analyzed, and it was identified that 1,884 genes were upregulated and 814 genes were downregulated in DLBCL compared with FL.

Based on the NetAffx annotation of the probe sets and the Refseq and Ensemble annotations of lncRNAs, a total of 2,448 IncRNA transcripts (corresponding to 1,970 IncRNA genes) were identified in the GSE58320 database. IncRNA
expression patterns between FL and DLBCL were compared, and a total of 123 lncRNAs were significantly upregulated and 192 lncRNAs were significantly downregulated (P<0.05) in DLBCL compared with FL.

**GO and KEGG analysis of differentially expressed mRNAs.**

To identify the potential functions of differentially expressed mRNAs, GO and KEGG analysis were performed using MAS 3.0 software. GO analysis indicated that the upregulated genes were primarily involved in the regulation of cell cycle, cell division, mitosis, DNA-dependent regulation of transcription and DNA replication, which are mainly associated with cell proliferation (Fig. 1A). KEGG pathway analysis revealed that upregulated genes were primarily enriched in pathways

---

**Figure 1.** GO and KEGG pathway analysis of differentially expressed mRNAs between follicular lymphoma and diffuse large B-cell lymphoma. (A) GO and (B) KEGG pathway analysis of the upregulated mRNAs. (C) GO and (D) KEGG pathway analysis of the downregulated mRNAs. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase; MHC, major histocompatibility complex; CAMs, cell adhesion molecules.
associated with cell cycle, pyrimidine metabolism, ubiquitin mediated proteolysis and Wnt signaling pathway (Fig. 1B).

Meanwhile, downregulated genes were mainly enriched in categories associated with transcription, immune response, interspecies interaction between organisms and signal transduction (Fig. 1C). These results suggest that these pathways may participate in regulating the transformation of FL. Downregulated genes were mainly associated with T cell receptor signaling pathway, cell adhesion molecules, cytokine-cytokine receptor interaction, MAPK signaling pathway and natural killer cell mediated cytotoxicity (Fig. 1D).

**GO and KEGG analysis of differentially expressed lncRNAs.** Co-expression networks were constructed to identify the association between differentially expressed mRNAs and lncRNAs using the GSE53820 dataset. The cut-off values used for selecting differentially expressed lncRNAs were a fold change ≥2 and P<0.05. GO and KEGG analyses were performed for each lncRNA using the set of co-expressed mRNAs.

In the present study, the top 500 differentially expressed lncRNAs and mRNAs were classified according to GO terms (Fig. 2A and C). GO analysis revealed that the
upregulated lncRNAs were enriched in transcription, cell cycle, cell division, mitosis, and protein amino acid phosphorylation (Fig. 2A), while the downregulated lncRNAs were enriched in transcription, transport, cell cycle, interspecies interaction between organisms, and oxidation reduction (Fig. 2C).

According to KEGG pathway analysis, upregulated lncRNAs were primarily enriched in pathways associated with cell cycle, T-cell receptor signaling pathway, pyrimidine metabolism and purine metabolism (Fig. 2B). Downregulated lncRNAs were enriched in pathways associated with cell cycle, purine metabolism, aminoacyl-tRNA biosynthesis and valine, leucine and isoleucine degradation (Fig. 2D).

Construction of the ceRNA networks. In order to investigate the molecular mechanisms of lncRNAs, the lncRNA-miRNA-mRNA axis was predicted in the present study. Firstly, the interactions between differentially expressed lncRNAs and their theoretical target miRNAs was predicted using the StarBase database (27). Then, TargetScan (28) and the StarBase database were employed to identify mRNAs targets that are suppressed by miRNAs. Finally, a co-expression network based on the association analysis between the differentially expressed lncRNAs and mRNAs was constructed. The lncRNA-mRNA interaction was integrated into the co-expression networks according to positive regulation and only gene pairs with |R| >0.5 were selected. lncRNA-miRNA-mRNA ceRNA networks involved in the transformation of DLBCL were constructed using Cytoscape 3.0 (http://www.cytoscape.org/).

The results of the present study revealed a specific DLBCL-associated and a specific FL-associated ceRNA network. As presented in Fig. 3, 14 lncRNAs, (including OIP5-AS1, SNHG16, HOXA11-AS and NUTM2A-AS1), 198 miRNAs, and >1,200 mRNAs were involved in the specific DLBCL-associated ceRNA network. It was revealed that the FL-associated ceRNA network included 8 lncRNAs, (including HCP5, COX10-AS1, PRKCQ-AS1 and LEMD1-AS1), 71 miRNAs, and >200 mRNAs (Fig. 4). The networks were constructed using Cytoscape 3.0.

Investigating the molecular functions of PRKCQ-AS1, HCP5, OIP5-AS1, growth arrest specific 5 (GAS5) and taurine upregulated 1 (TUG1). According to the ceRNA networks, it was revealed that PRKCQ-AS1, HCP5, OIP5-AS1, GAS5 and TUG1 functioned as key regulators (Figs. 5 and 6). However, the molecular functions of PRKCQ-AS1, HCP5, OIP5-AS1, GAS5 and TUG1 in the transformation of DLBCL remain unknown. By analyzing co-expressed mRNAs, it was revealed that TUG1, OIP5-AS1 and GAS5 were associated with anti-apoptosis, cell cycle, DNA repair, mitosis, transcription, mitosis, G2/M transition of mitotic cell cycle and protein amino acid phosphorylation functions (Fig. 5). PRKCQ-AS1
was associated with the response to oxidative stress, regulation of smooth muscle cell proliferation and acute-phase response functions (Fig. 6). HCP5 was associated with transcription, cell adhesion, lipid metabolism and immune response functions (Fig. 6).

Discussion

The molecular mechanisms involved in the transformation of DLBCL had previously been unclear. Therefore, it was critically important to investigate the biological mechanisms of DLBCL. In the present study, differentially expressed mRNAs and lncRNAs between FL and DLBCL were identified using the GEO database accession no. GSE53820. Subsequently, a specific DLBCL-associated ceRNA network and a specific FL-associated ceRNA network were constructed. GO and KEGG pathway analyses revealed that differentially expressed lncRNAs served key functions in regulating signal transduction, transcription, cell adhesion, development and protein amino acid phosphorylation.

DLBCL is a malignancy with a high mortality rate due to a lack of biomarkers for early diagnosis and efficient therapeutic strategies (3). Previously, studies had indicated that lncRNAs served key functions in tumorigenesis, cancer progression and metastasis (3,4). An increasing number of studies have additionally demonstrated that the expression of lncRNAs may be deregulated in various types of human cancer, including DLBCL (9,10,17). In prostate cancer, Crea et al (29) identified prostate cancer associated transcript 18 as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Wan et al (30) also reported that androgen-responsive lncRNAs may function as biomarkers for prostate cancer. In the present study, differentially expressed mRNAs and lncRNAs between FL and DLBCL were identified using a publicly available gene expression database, GSE53820. From the microarray expression profiles, it was identified that 1,654 genes were upregulated and 1927 genes were downregulated in DLBCL compared with FL. It was also revealed that 152 lncRNAs were significantly upregulated, and 37 lncRNAs were significantly downregulated between the DLBCL and FL groups.
In order to predict the functions of the differentially expressed lncRNAs, co-expression networks were constructed and GO and KEGG analysis was performed for each lncRNA by using a set of co-expressed mRNAs. According to the KEGG pathway analysis, upregulated lncRNAs were primarily enriched in pathways associated with the cell cycle, T cell receptor signaling pathway, pyrimidine metabolism and purine metabolism. Downregulated lncRNAs were enriched in pathways associated with cell cycle, purine metabolism, aminoacyl-tRNA biosynthesis and degradation of valine, leucine and isoleucine. GO analysis revealed that the upregulated lncRNAs were enriched in transcription, cell cycle, cell division, mitosis, and protein amino acid phosphorylation, whilst the downregulated lncRNAs were enriched in transcription, transport, cell cycle, interspecies interaction between organisms and oxidation reduction.

Previously, a number of reports had revealed that the altered expression of certain lncRNAs may be an important mechanism of DLBCL progression. A number of lncRNAs, including HOTAIR (17), LincRNA-p21 (18) and PEG10 (19) were significantly associated with the progression of DLBCL. However, the molecular mechanisms and functions underlying the involvement of lncRNAs in the transformation of DLBCL remain largely unknown. In the present study, in order to investigate the molecular mechanisms involved in the regulation of DLBCL progression by lncRNAs, lncRNA-miRNA-mRNA ceRNA networks were constructed based on our analysis. From the present study, it was revealed that TUG1, PVT1, MALAT1 and HCP5 served key functions in lncRNA-mediated ceRNA networks. According to GO analysis, the molecular functions of TUG1, PVT1, MALAT1 and HCP5 in DLBCL were investigated. According to the ceRNA networks constructed in the present study, it was revealed that PRKCCQ-ASI, HCP5, OIP5-ASI, GAS5 and TUG1 functioned as key regulators. However, the molecular functions of PRKCCQ-ASI, HCP5,
OIP5-AS1, GAS5 and TUG1 in the transformation of DLBCL remained unknown. By analyzing co-expressed mRNAs, it was revealed that TUG1, OIP5-AS1 and GAS5 were associated with anti-apoptosis, cell cycle, DNA repair, mitosis, transcription, mitosis, G2/M transition of mitotic cell cycle and protein amino acid phosphorylation. PRKCQ-AS1 was associated with the response to oxidative stress, regulation of smooth muscle cell proliferation and acute-phase response. HCP5 was associated with transcription, cell adhesion, lipid metabolism and immune response.

In conclusion, differently expressed lncRNAs between FL and DLBCL were identified for the first time, screened by using a microarray. Compared with FL, a total of 123 upregulated lncRNAs and 192 downregulated lncRNAs in DLBCL were identified. Subsequently, a specific DLBCL-associated ceRNA network and a specific FL-associated ceRNA network.

Figure 6. Analysis of the associated molecular functions of PRKCQ-AS1 and HCP5 in the transformation of diffuse large B-cell lymphoma. Triangle nodes represent lncRNAs, circular nodes represent biological processes and square nodes represent mRNAs. PRKCQ-AS1, PRKCQ antisense RNA; HCP5, HLA complex P5 (non-protein coding).
were constructed. GO and KEGG pathway analyses revealed that differentially expressed lncRNAs served key functions in regulating signal transduction, transcription, cell adhesion, development and protein amino acid phosphorylation. The present study would provide a potential novel therapeutic and prognostic target for the treatment of DLBCL.

Acknowledgements

The present study is supported by the Program of Education Department of Zhejiang Province (grant no. Y201223954).

References

1. Prochazka V, Papajik T, Jarosova M and Indrak K: Prognostic factors in follicular lymphoma in the rituximab era: How to identify a high-risk patient? Biomed Pap Fac Univ Palacky Olomouc Czech Repub 155: 99-108, 2011.
2. Martinez-Climen JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo E, Albertsson DG, Garcia-Conde J, Dyer MJ, Levy R, Pinkel D and Lossos IS: Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 101: 3109-3117, 2003.
3. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguirre GC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68-74, 2002.

4. Li SP, Xu HX, Yu Y, He JD, Wang Z, Xu YJ, Wang CY, Zhang HM, Zhang RX, Zhang JJ, et al: lncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget 7: 42431-42446, 2016.
5. Li H, Yu B, Li J, Su L, Yan M, Zhu Z and Liu B: Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 5: 2318-2329, 2014.
6. Hangauer MJ, Vaughn IW and McManus MT: Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet 9: e1003569, 2013.
7. Kim T, Cui R, Jeon YJ, Fadda P, Alder H and Croce CM: MYC-repressed long noncoding RNAs antagonize MYC-induced cell proliferation and cell cycle progression. Oncotarget 6: 18780-18789, 2015.
8. Geisler S and Coller J: RNA in unexpected places: Long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 14: 699-712, 2013.
9. Li CH and Chen Y: Targeting long non-coding RNAs in cancers: Progress and prospects. Int J Biochem Cell Biol 45: 1895-1910, 2013.
10. Tang JY, Lee JC, Chang YT, Hou MF, Huang HW, Liaw CC and Chang HW: Long noncoding RNAs related to the tumors, cancers, and drugs. ScientificWorldJournal 2013: 943539, 2013.
11. Dijkstra S, Mulders PF and Schalken JA: Clinical use of novel urine and blood based prostate cancer biomarkers: A review. Clin Biochem 47: 889-896, 2014.
12. Ariel I, Miao HQ, Ji XR, Schneider T, Roll D, de Groot N, Hochberg A and Ayesh S: Imprinted H19 oncetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol 51: 21-25, 1998.
13. Salmena L, Poliseno L, Tay Y, Kats L and Pandolfo M: A ceRNA hypothesis: The Rosetta stone of a hidden RNA language? Cell 146: 353-358, 2011.
14. Giza DE, Vasiilescu C and Calin GA: MicroRNAs and ceRNAs: Therapeutic implications of RNA networks. Expert Opin Biol Ther 14: 1285-1293, 2014.
15. Zhou M, Diao Z, Yue X, Chen Y, Zhao H, Cheng L and Sun J: Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer. Oncotarget 7: 56383-56394, 2016.
16. Zhou M, Wang X, Shi H, Cheng L, Wang Z, Zhao H, Yang L and Sun J: Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer. Oncotarget 7: 12598-12611, 2016.
17. Yan Y, Han J, Li Z, Yang H, Sui Y and Wang M: Elevated RNA expression of long non-coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B-cell lymphoma. Mol Med Rep 13: 5125-5131, 2016.
18. Peng W, Wu J and Feng J: LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Clin Exp Med 17: 1-8, 2017.
19. Peng W, Fan H, Wu G, Wu J and Feng J: Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenocity. Clin Exp Med 16: 177-182, 2016.
20. Sun J, Cheng L, Shi H, Zhang Z, Zhao H, Wang Z and Zhou M: A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma. Sci Rep 6: 27842, 2016.
21. Peng W, Wu J and Feng J: Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomed Pharmacother 79: 263-268, 2016.
22. Peng W and Feng J: Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma. Biomed Pharmacother 77: 65-71, 2016.
23. Zhou M, Zhao H, Xu W, Bao S, Cheng L and Sun J: Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. Mol Cancer 16: 16, 2017.
24. Brodtkorb M, Lingjaerde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, et al: Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood 123: 1051-1054, 2014.
25. Zhang X, Sun S, Pu JK, Tsang AC, Lee D, Man VO, Lui WM, Wong ST and Leung GK: Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol Dis 48: 1-8, 2012.
26. Gutmann M and Rinn JL: Modular regulatory principles of large non-coding RNAs. Nature 482: 339-346, 2012.
27. Shen X, Xie B, Ma Z, Yu W, Wang W, Xu D, Yan X, Chen B, Yu L, Li J, et al: Identification of novel long non-coding RNAs in triple-negative breast cancer. Oncotarget 6: 21730-21739, 2015.
28. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
29. Crea F, Watabiki A, Quagliati L, Xue H, Pikor L, Paroliva A, Wang Y, Lin D, Lam WL, Farrar WL, et al: Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 5: 764-774, 2014.
30. Wang X, Huang W, Yang S, Zhang Y, Pu H, Fu F, Huang Y, Wu H, Li T and Li Y: Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer. Oncotarget 7: 60503-60518, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.